DRRX Stock Overview
A biopharmaceutical company, develops medicines based on its epigenetic regulator program.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
DURECT Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.15 |
52 Week High | US$3.36 |
52 Week Low | US$0.47 |
Beta | 1.03 |
11 Month Change | -15.44% |
3 Month Change | 23.66% |
1 Year Change | -61.79% |
33 Year Change | -90.65% |
5 Year Change | -92.48% |
Change since IPO | -99.20% |
Recent News & Updates
Recent updates
Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts
Aug 08Durect names ex-RBC Capital Markets executive as CFO
Jul 05Is DURECT (NASDAQ:DRRX) A Risky Investment?
May 12DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be
Mar 14DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 10Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?
Jan 08Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?
Aug 05Durect (DRRX) Investor Presentation - Slideshow
May 06Durect EPS misses by $0.01, misses on revenue
May 04DURECT prices ~$43M stock offering
Feb 04DURECT surges after FDA approval for Posimir
Feb 02Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.
Dec 16DURECT (DRRX) Investor Presentation - Slideshow
Oct 31Shareholder Returns
DRRX | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -21.8% | 4.0% | 4.0% |
1Y | -61.8% | 16.1% | 24.9% |
Return vs Industry: DRRX underperformed the US Pharmaceuticals industry which returned 15.4% over the past year.
Return vs Market: DRRX underperformed the US Market which returned 21.7% over the past year.
Price Volatility
DRRX volatility | |
---|---|
DRRX Average Weekly Movement | 15.7% |
Pharmaceuticals Industry Average Movement | 10.1% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: DRRX's share price has been volatile over the past 3 months.
Volatility Over Time: DRRX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 48 | Jim Brown | www.durect.com |
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals.
DURECT Corporation Fundamentals Summary
DRRX fundamental statistics | |
---|---|
Market cap | US$41.28m |
Earnings (TTM) | -US$15.80m |
Revenue (TTM) | US$8.41m |
4.2x
P/S Ratio-2.3x
P/E RatioIs DRRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DRRX income statement (TTM) | |
---|---|
Revenue | US$8.41m |
Cost of Revenue | US$20.79m |
Gross Profit | -US$12.38m |
Other Expenses | US$3.42m |
Earnings | -US$15.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.51 |
Gross Margin | -147.21% |
Net Profit Margin | -187.84% |
Debt/Equity Ratio | 249.1% |
How did DRRX perform over the long term?
See historical performance and comparison